UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE NONCONTROLLING INTERESTS AND SHAREHOLDERS' EQUITY - USD ($) $ in Millions	Total	Redeemable Noncontrolling Interests	Common Stock	Treasury Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (loss) Income, net of tax	Total Shareholders' Equity Attributable to Bruker Corporation	Noncontrolling Interests in Consolidated Subsidiaries
Balance at beginning of period at Dec. 31, 2022	$ 1,125.7	$ 6.1	$ 1.7	$ (1,085.0)	$ 256.3	$ 1,926.0	$ 14.8	$ 1,113.8	$ 11.9
Balance (in shares) at Dec. 31, 2022			147,023,144	28,366,442
Increase (Decrease) in Stockholders' Equity
Stock options exercised	0.7				0.7			0.7
Stock options exercised (in shares)			34,957
Restricted Stock units vested	(0.1)				(0.1)			(0.1)
Restricted Stock units vested (in shares)			18,463
Stock based compensation	4.1				4.1			4.1
Employee stock purchase plan	0.2				0.2			0.2
Shares Repurchased	(22.3)			$ (22.2)	(0.1)			(22.3)
Shares Repurchased (in shares)			(315,318)	315,318
Cash dividends declared and paid to common shareholders	(7.4)					(7.4)		(7.4)
Biognosys acquisition - other shareholders		2.3
Other shareholders of majority-owned acquisitions		3.6
Proceeds from the sale of noncontrolling interests	5.3								5.3
Consolidated net (loss) income	77.5	(0.1)				76.5		76.5	1.0
Other comprehensive income	15.1	0.1					14.8	14.8	0.3
Balance at end of period at Mar. 31, 2023	1,198.8	12.0	$ 1.7	$ (1,107.2)	261.1	1,995.1	29.6	1,180.3	18.5
Balance (in shares) at Mar. 31, 2023			146,761,246	28,681,760
Balance at beginning of period at Dec. 31, 2023	1,394.6	18.7	$ 1.7	$ (1,237.2)	282.9	2,323.8	6.0	1,377.2	17.4
Balance (in shares) at Dec. 31, 2023			145,164,826	30,778,879
Increase (Decrease) in Stockholders' Equity
Stock options exercised	3.4				3.4			3.4
Stock options exercised (in shares)			146,765
Restricted Stock units vested (in shares)			23,051
Stock based compensation	4.6				4.6			4.6
Employee stock purchase plan	0.2				0.2			0.2
Cash dividends declared and paid to common shareholders	(7.3)					(7.3)		(7.3)
Loans to noncontrolling interest	(0.9)								(0.9)
Consolidated net (loss) income	52.3	(0.3)				50.9		50.9	1.4
Other comprehensive income	(13.7)	(0.5)					(13.7)	(14.0)	(0.3)
Balance at end of period at Mar. 31, 2024	$ 1,432.9	$ 17.9	$ 1.7	$ (1,237.2)	$ 291.1	$ 2,367.4	$ (7.7)	$ 1,415.3	$ 17.6
Balance (in shares) at Mar. 31, 2024			145,334,642	30,778,879